Advertisement

Topics

A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-Remitting Multiple Sclerosis (MS)

2014-08-27 03:46:04 | BioPortfolio

Summary

This was an open-label, randomized, multicenter, comparative, parallel-group study comparing the therapeutic effects of two IFN-beta-1a regimens in relapsing-remitting multiple sclerosis. The primary objective was to demonstrate the superiority of Rebi®f 44 mcg SC given three times a week (132 mcg per week) to that of Avonex® 30 mcg IM given once a week.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Multiple Sclerosis, Relapsing-Remitting

Intervention

Rebif® 44 mcg three times per week subcutaneously (SubQ), Avonex® 30 mcg once weekly intramuscularly (IM)

Status

Completed

Source

EMD Serono

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:46:04-0400

Clinical Trials [562 Associated Clinical Trials listed on BioPortfolio]

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with Rebif (interferon beta-1a) in patients with relaps...

Transition to Rebif New Formulation

To assess patient satisfaction with respect to the incidence of flu-like symptoms in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon be...

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with Rebif (interferon beta -1a) in patients with rela...

Tolerability of Rebif® Injection With and Without the Use of Rebiject™ Mini in Relapsing Remitting Multiple Sclerosis Patients

A randomized, multicenter, parallel-group open-label study comparing the tolerability of Rebif® injections (44 mcg administered subcutaneously three times a week) with and without Rebijec...

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central ...

PubMed Articles [5257 Associated PubMed Articles listed on BioPortfolio]

Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability.

Human recombinant interferon beta (IFN-β) is one of the first line treatments for Relapsing-Remitting Multiple Sclerosis (RRMS). However, the production of neutralizing antibodies (NAb) can impair it...

Brain methylmercury uptake in fetal, neonate, weanling, and adult rats.

Fetuses and neonates are known to be highly susceptible to methylmercury (MeHg) toxicity, but little is known about the relative uptake of MeHg from blood to the developing brain. We measured time-cou...

Reflux after esophagectomy with gastric conduit reconstruction in the posterior mediastinum for esophageal cancer: original questionnaire and EORTC QLQ-C30 survey.

Reflux following an esophagectomy with gastric conduit reconstruction in the posterior mediastinum is a clinically significant problem. In this study, we investigated the frequency and impact of reflu...

Tn (N-acetyl-d-galactosamine-O-serine/threonine) immunization protects against hyperoxia-induced lung injury in adult mice through inhibition of the nuclear factor kappa B activity.

Prolonged hyperoxia exposure leads to inflammation and acute lung injury. Since hyperoxia activates nuclear factor kappa B (NF-κB) and proinflammatory mediators in lung fibroblasts and murine lungs, ...

Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo.

Oesophageal squamous cell carcinoma (OSCC) is highly prevalent in developing countries but there has been little recent progress into efficacious yet affordable treatment strategies. Drug repurposing ...

Medical and Biotech [MESH] Definitions

A species of European freshwater LEECHES used for BLOODLETTING in ancient times and also for LEECHING in modern times.

Blood infection that occurs in an infant younger than 90 days old. Early-onset sepsis is seen in the first week of life and most often appears within 24 hours of birth. Late-onset occurs after 1 week and before 3 months of age.

The at-home administering of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously or by some other non-alimentary route.

The administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered by a route other than the alimentary canal (e.g., intravenously, subcutaneously).

Therapy for MOVEMENT DISORDERS, especially PARKINSON DISEASE, that applies electricity via stereotactic implantation of ELECTRODES in specific areas of the BRAIN such as the THALAMUS. The electrodes are attached to a neurostimulator placed subcutaneously.

More From BioPortfolio on "A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-Remitting Multiple Sclerosis (MS)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial